Platelet activating factor levels and metabolism in tangier disease: a case study

被引:4
|
作者
Kolovou, Vana [1 ,2 ,3 ]
Papakonstantinou, Vasiliki D. [3 ]
Stamatakis, George [3 ]
Verouti, Sophia N. [3 ]
Xanthopoulou, Marianna N. [4 ]
Kolovou, Genovefa [1 ,2 ]
Demopoulos, Constantinos A. [3 ]
机构
[1] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece
[2] Onassis Cardiac Surg Ctr, Mol Immunol Lab, Athens, Greece
[3] Univ Athens, Fac Chem, Biochem Lab, Athens 11528, Greece
[4] Harokopio Univ, Dept Sci Nutr Dietet, Athens, Greece
关键词
PAF; Tangier Disease; Atherosclerosis; Lp-PLA(2); PAF-AH; Lyso-PAF-AT; PAF-CPT; ACETYLHYDROLASE PAF-AH; CASSETTE TRANSPORTER 1; DENSITY-LIPOPROTEIN; PHOSPHOLIPASE A(2); PLASMA; BINDING; CHOLESTEROL; BLOOD; VIVO; LEUKOCYTES;
D O I
10.1186/1476-511X-11-89
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Tangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. On the other hand the pivotal role of Platelet-Activating Factor (PAF) mediator in atheromatosis was found. Plasma lipoproteins are transporters of the PAF acetylhydrolase (PAF-AH) in cells and known as lipoprotein-phospholipase A(2) (Lp-PLA(2)) in plasma and regulators of PAF levels in blood. In addition, PAF can be biosynthesized from the remodeling and the de novo pathways in which Lyso-platelet activating factor-acetyltransferase (Lyso-PAF-AT) and platelet activating factor-cholinephosphotransferase (PAF-CPT) are the regulatory enzymes. The aim of this study is to investigate in a TD patient with a unique mutation (C2033A), the concentration of PAF in blood, the Equivalent Concentration for 50% aggregation (EC50) values of platelet rich plasma (PRP) toward PAF, adenosine diphosphate (ADP) and thrombin, and the activities of PAF metabolic enzymes Lp-PLA(2), PAF-AH, Lyso-PAF-AT and PAF-CPT. Methods: The EC50 value of PRP was measured by an aggregometer. The determination of the specific activity of PAF-CPT and Lyso-PAF-AT was made after in vitro enzymatic assay, chromatographic separation and measurement of the produced PAF in a biological assay with washed rabbit platelets. The determination of PAF-AH and Lp-PLA(2) was made after an in vitro enzymatic assay from the decay of radioactive PAF. Results: The TD patient had lower bound-PAF values in blood, decreased specific activity of PAF-CPT and Lyso-PAF-AT, increased specific activity of PAF-AH in platelets and leukocytes and Lp-PLA(2) activity in plasma compared to healthy women. The EC50 of PAF and Thrombin were higher compared to healthy women. Conclusion: The increased Lp-PLA(2) activity, as well as, the decreased activities of PAF-CPT and Lyso-PAF-AT, explain the decreased bound-PAF level in TD patient and the EC50 of PAF. However, total PAF is in a normal range and this probably can explain one of the reasons this TD patient has no CAD.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Platelet activating factor levels and metabolism in tangier disease: a case study
    Vana Kolovou
    Vasiliki D Papakonstantinou
    George Stamatakis
    Sophia N Verouti
    Marianna N Xanthopoulou
    Genovefa Kolovou
    Constantinos A Demopoulos
    Lipids in Health and Disease, 11
  • [2] Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control Study
    Zheng, Guo-Hua
    Xiong, Shang-Quan
    Mei, Li-Juan
    Chen, Hai-Ying
    Wang, Ting
    Chu, Jian-Feng
    INFLAMMATION, 2012, 35 (04) : 1419 - 1428
  • [3] Elevated Plasma Platelet Activating Factor, Platelet Activating Factor Acetylhydrolase Levels and Risk of Coronary Heart Disease or Blood Stasis Syndrome of Coronary Heart Disease in Chinese: A Case Control StudyA Case–Control Study
    Guo-Hua Zheng
    Shang-Quan Xiong
    Li-Juan Mei
    Hai-Ying Chen
    Ting Wang
    Jian-Feng Chu
    Inflammation, 2012, 35 : 1419 - 1428
  • [4] Metabolism of platelet activating factor in lung
    Snyder, Fred
    Blank, Merle L.
    Lee, Ten-Ching
    Annals of the New York Academy of Sciences, 1991, 629
  • [5] METABOLISM OF PLATELET-ACTIVATING-FACTOR IN LUNG
    SNYDER, F
    BLANK, ML
    LEE, TC
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1991, 629 : 168 - 175
  • [6] The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease
    Hikiji, Hisako
    Takato, Tsuyoshi
    Shimizu, Takao
    Ishii, Satoshi
    PROGRESS IN LIPID RESEARCH, 2008, 47 (02) : 107 - 126
  • [7] THE DEGRADATION OF PLATELET-ACTIVATING-FACTOR IN THE PLASMA OF A PATIENT WITH FAMILIAL HIGH-DENSITY-LIPOPROTEIN DEFICIENCY (TANGIER DISEASE)
    PRITCHARD, PH
    CHONN, A
    YEUNG, CCH
    BLOOD, 1985, 66 (06) : 1476 - 1478
  • [8] PLATELET-ACTIVATING FACTOR METABOLISM IN HUMAN AMNION AND THE RESPONSES OF THIS TISSUE TO EXTRACELLULAR PLATELET-ACTIVATING FACTOR
    BILLAH, MM
    DIRENZO, GC
    BAN, C
    TRUONG, CT
    HOFFMAN, DR
    ANCESCHI, MM
    BLEASDALE, JE
    JOHNSTON, JM
    PROSTAGLANDINS, 1985, 30 (05): : 841 - 850
  • [9] Metabolism and the biological role of platelet-activating factor
    Gegotek, Agnieszka
    Skrzydlewska, Elzbieta
    ALERGIA ASTMA IMMUNOLOGIA, 2015, 20 (02): : 79 - 84
  • [10] REGULATION OF THE METABOLISM AND BINDING OF PLATELET-ACTIVATING FACTOR
    OFLAHERTY, JT
    ISI ATLAS OF SCIENCE-PHARMACOLOGY, 1988, 2 (04): : 314 - 318